Life sciences company EKF Diagnostics Holdings plc (AIM: EKF) has acquired technology assets from Sweden-based Beep Insights AB, including its iOS and Android application designed for real-time glucose and lactate tracking in sports performance monitoring.
The Beep Insights Technology integrates data from Bluetooth-connected wearables with biomarker tracking to deliver personalised training metrics. The acquisition is expected to enhance EKF's existing Sports Performance portfolio, particularly its Lactate Scout Sport handheld analyser, which is already compatible with the application.
EKF has collaborated with Beep Insights and its chief executive officer, Peter Alex, to integrate the software and improve accessibility in determining lactate threshold and optimising training outcomes. Following completion of the transaction, Alex will join EKF to support further development, including the application of artificial intelligence in performance training.
Headquartered in Penarth, Wales, EKF Diagnostics is a global diagnostics business specialising in point-of-care analysers for haematology and diabetes. The company operates manufacturing sites in the US and Germany and serves customers in more than 120 countries.
Aroa Biosurgery reports significantly improved healing of diabetic foot ulcers in Symphony trial
Lilly reports positive 48-week Phase 2b resu;ts for EloraTZP
Revvity launches IVDR-certified solution for early detection of type 1 diabetes
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Bayer's Kerendia wins FDA approval for chronic kidney disease associated with type 1 diabetes
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Nippon Kinzoku begins mass production of ultra-thin stainless steel for insulin needles
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV